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The PI3K (phosphoinositide 3-kinase) pathway is commonly
activated in cancer as a consequence of inactivation of the tumour
suppressor PTEN (phosphatase and tensin homologue deleted on
chromosome10),amajornegativeregulatorofPI3Ksignalling.In
line with this important role of PTEN, mice that are heterozygous
for a PTEN-null allele (PTEN
+/− mice) spontaneously develop a
varietyoftumoursinmultipleorgans.PTENisaphosphatasewith
selectivity for PtdIns(3,4,5)P3, which is produced by the class I
isoforms of PI3K (p110α, p110β, p110γ and p110δ). Previous
studies indicated that PTEN-deﬁcient cancer cell lines mainly
depend on p110β, and that p110β, but not p110α, controls mouse
prostate cancer development driven by PTEN loss. In the present
study, we investigated whether the ubiquitously expressed p110α
can also functionally interact with PTEN in cancer. Using genetic
mouse models that mimic systemic administration of p110α-
or p110β-selective inhibitors, we conﬁrm that inactivation of
p110β, but not p110α, inhibits prostate cancer development in
PTEN
+/− mice, but also ﬁnd that p110α inactivation protects
from glomerulonephritis, pheochromocytoma and thyroid cancer
induced by PTEN loss. This indicates that p110α can modulate
the impact of PTEN loss in disease and tumourigenesis. In
primary and immortalized mouse ﬁbroblast cell lines, both
p110α and p110β controlled steady-state PtdIns(3,4,5)P3 levels
and Akt signalling induced by heterozygous PTEN loss. In
contrast, no correlation was found in primary mouse tissues
between PtdIns(3,4,5)P3 levels, PI3K/PTEN genotype and cancer
development. Taken together, our results from the present study
show that inactivation of either p110α or p110β can counteract
the impact of PTEN inactivation. The potential implications of
these ﬁndings for PI3K-targeted therapy of cancer are discussed.
Key words: cancer,kinase isoform, lipid signalling, phosphoinos-
itide 3-kinase (PI3K), phosphatase and tensin homologue deleted
on chromosome 10 (PTEN), tumour suppressor.
INTRODUCTION
PI3Ks (phosphoinositide 3-kinases) are a family of lipid kinases
that catalyse the production of the lipid second messenger
PtdIns(3,4,5)P3 in cellular membranes [1]. PtdIns(3,4,5)P3 and
its degradation product, PtdIns(3,4)P2, interact with a variety
of intracellular downstream protein effectors such as the Akt
protein kinase, adaptor proteins and regulators of small GTPases,
whichultimatelycontrolcellproliferation,survivalandmigration
[2,3]. Overactivation of the PI3K signalling cascade leads
to deregulation of these cellular processes, contributing to
cancer development and progression. A common mechanism of
constitutive PI3K activation in cancer results from loss or loss-of-
functionofthePTEN(phosphataseandtensinhomologuedeleted
on chromosome 10) tumour suppressor, a lipid phosphatase that
converts PtdIns(3,4,5)P3 into PtdIns(4,5)P2, hereby terminating
the PI3K signal [4–7]. Heterozygous PTEN-null mice (PTEN
+/−
mice) spontaneously develop many different tumours [8–10]. In
addition to its lipid phosphatase activity [11], there is increasing
evidence that a PI3K-independent protein phosphatase activity of
PTEN [12–14] and/or phosphatase-independent activities in the
nucleus [15,16] also contribute to the tumour suppressor function
of PTEN.
Among the eight isoforms of PI3K in mammals, only class I
PI3KsgeneratePtdIns(3,4,5)P3,thelipidsubstrateforPTEN[17].
Class I PI3Ks consist of a p110 catalytic subunit (p110α, p110β,
p110γ or p110δ) complexed to a regulatory subunit that targets
the p110 subunit to the plasma membrane upon stimulation of
tyrosine kinase or G-protein-coupled receptors [3]. PIK3CA,t h e
gene encoding p110α, is the only PI3K catalytic subunit gene
found to be mutated in cancer [18], leading to its overactivation.
Initial studies showed that inactivation of PTEN and the presence
of oncogenic PIK3CA mutations did not co-occur in cancer [19–
21]. However, additional work has shown that these two genetic
alterations can co-exist, for example in endometrial carcinoma,
where PTEN loss and mutant PIK3CA lead to a higher activation
of the PI3K pathway and a possible co-operation towards a more
invasive phenotype [22].
Previous studies have indicated that aberrant PI3K signalling
and tumorigenesis due to PTEN deﬁciency mainly rely on p110β
activity. This is the case in several PTEN-deﬁcient cancer cell
lines that seem to depend on p110β for proliferation [23,24]. In
addition, conditional knockout of p110β, but not of p110α,w a s
found to impair cancer development induced by prostate-speciﬁc
PTEN loss in a mouse model [24,25].
In the present study, we used PTEN
+/− mice and cells as a
broader genetic screen of PTEN inactivation to assess the role
of p110α and p110β in PTEN-induced tumourigenesis. Although
global inactivation of p110α in PTEN
+/− mice did not protect
from a wide spectrum of tumours, including prostate cancer, the
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incidenceofotherpathologiessuchasglomerulonephritis,thyroid
tumours and phaechromocytoma was reduced, documenting that
p110α can also control biological effects induced by PTEN
loss. p110α could also dampen enhanced PtdIns(3,4,5)P3
production and PI3K signalling in cultured PTEN
+/− cell lines.
The implications of these ﬁndings for PI3K-targeted cancer
therapy are discussed.
EXPERIMENTAL
Small molecule inhibitors
TGX-221 and LY294002 were from Calbiochem.
Isolation and immortalization of MEFs (mouse embryonic
ﬁbroblasts)
E13.5 (embryonic day 13.5) embryos were homogenized,
dissociated with trypsin and cells allowed to adhere on tissue
culture dishes for 2–3 days in DMEM (Dulbecco’s modiﬁed
Eagle’s medium) containing 10% FBS (fetal bovine serum) until
conﬂuent. Early passage MEFs (passage 2) were immortalized by
transduction with a puromycin resistance-containing retrovirus
expressing a microRNA-based shRNA (short hairpin RNA)
against p53 [26]. After retroviral infection, MEFs were selected
with 1 μg/ml puromycin (Sigma) for 10 days.
Quantiﬁcation of PtdIns(3,4,5)P3
PtdIns(3,4,5)P3 was measured in extracts from MEFs or tissue
samples using a time-resolved FRET (F¨ orster resonance energy
transfer) assay [27]. For MEFs, medium was aspirated from
10 cm
2 dishes of cells and 0.5 ml of ice-cold 0.5 M TCA
(trichloroacetic acid) was added immediately and allowed to
stand on ice for 5 min. The cells were then scraped off, the wells
rinsed with additional TCA if required, and the precipitate was
pelleted.Neutrallipidswereextractedfromthepelletwith1 mlof
methanol/chloroform (2:1, v/v) by vortex-mixing 3–4 times over
a 10 min period at room temperature (22◦C) and the solvent was
discarded.Theacidiclipidswerethenextractedasfollows:500 μl
of chloroform/methanol/12 M HCl (40:80:1, by vol.) was added
to the pellet and vortexed occasionally over a 15 min period at
room temperature. Chloroform (180 μl) and 0.1 M HCl (300 μl)
were then added, vortex-mixed and centrifuged (2000 g for
1 min) to separate the organic phase. The organic phase was then
collectedintoacleantubeanddriedinaspeedvacuumcentrifuge.
The lipids were resuspended by sonication [using a Sonics Vibra-
Cell
TM setto42 Woutput;15 spulsepersampleinawater-cooled
cup sonicator probe at 5◦C( S i g m a ) ]i n6 0μl of assay buffer
(50 mM Tris/HCl, pH 7.0, 150 mM NaCl, 1 mM dithiothreitol,
0.5 mM EGTA and 1.2% sodium cholate). The mass of inositol
lipid was estimated by adding 25 μl of the re-suspended lipid to
25 μl of detection mix as described previously [27].
The extracts from tissue samples were prepared in a similar
manner, with the biopsy samples being snap frozen in liquid
nitrogen and stored at −80◦C until required. The tissue samples
were thawed into 0.5 M TCA, centrifuged and the pellet extracted
as described for the MEFs above. The protein content of the
samples (both MEFs and tissue) was estimated by adding 1 ml of
acetone to the acidic solvent extraction after removal of the lipid-
containing lower phase and the protein was pelleted by centrifu-
gation (10000 g for 5 min). After removal of the acetone and air
drying,theproteinpelletwasre-dissolvedbyincubationovernight
at 50◦Ci n5 % (w/v) SDS and 0.2 M NaOH. The dissolved
protein was diluted as required and the protein concentration was
estimated using a Pierce micro BCA (bichinchonic acid) kit as
per the manufacturer’s instructions. The mass of PtdIns(3,4,5)P3
estimated by the time-resolved-FRET assay was then expressed
as pmol PtdIns(3,4,5)P3/mg of total protein.
Cell lysis and immunoblot analysis
Cells lysis buffer contained 50 mM Tris/HCl, pH 7.4, 5 mM
EDTA, 150 mM NaCl, 50 mM NaF and 1% Triton X-100,
supplemented with 2 mg/ml aprotinin, 1 mM pepstatin, 1 ng/ml
L-leupeptin, 1 mM PMSF and 1 mM Na3VO4. Lysates were
analysed by SDS/PAGE and immunoblotting using antibodies
against pThr
24/Thr
32-Foxo3a (where p is phosphorylated and Fox
is forkhead box) (9464), pThr
308-Akt (4056), pSer
473-Akt (4058),
total Akt (9272), pSer
240/Ser
244-S6 (2215) and total ribosomal
S6 (2217), all from Cell Signaling Technology. Quantitation of
immunoblot signal intensity was performed with a Bio-Rad GS-
800 densitometer and QuantityOne software.
Mice
Mice were kept in individually-ventilated cages and cared for
according to U.K. Home Ofﬁce regulations. The generation and
genotyping of PTEN
+/− [10] and the p110α
D933A/WT (where WT,
wild-type) mice have been described previously [28]. These
mouse lines were backcrossed to the C57BL/6 background
for >10 generations before initiating the intercrosses for the
present study. p110β
D931A/WT mice were on a 129/Sv back-
ground backcrossed for six generations onto the C57BL/6
background. The difference in genetic background between the
p110α and p110β experimental groups was controlled for by
using two independent PTEN
+/− control cohorts, made up of
respectivelittermatesofthePI3K×PTENintercrosses.Micewere
maintained under standard husbandry conditions for a period of
up to 16 months of age. During this time, animals were monitored
weekly and killed if they became unwell, exhibited reduced body
weight or an obvious external tumour of over 1.44 cm
3. Killed
animals were subjected to necropsy and pathological analysis
after ﬁxation of tissues in 4% paraformaldehyde.
Histological analysis of tumours and immunohistochemistry
For histological analysis, tissues were immersion-ﬁxed in either
4% paraformaldehyde or 10% neutral-buffered formalin. Small
blocksfromalltissuesweresampledfollowingdissection,further
ﬁxed and processed. They were then processed to parafﬁn
wax blocks, where sections of 6 microns were cut and stained
with haematoxylin and eosin. Further sections were stained with
periodic acid Schiff without prior diastase digestion as required.
Primary antibodies were used to detect B220/CD45R (RA3-
6B2, BD Pharmingen), CD79αcy (HM57, Dako), CD3 (F7.2.38,
Dako) and Ki67 (VP-K452, Vector Laboratories) to characterise
lymphomas. Antibodies against PTEN (9188), FOXO1 (9462),
pSer
473-Akt (3787) and pSer
235/Ser
236-S6 (4857) were purchased
from Cell Signaling Technology and used to probe the tumours.
Antibody binding was visualized using Vectastain reagents and
protocols performed on a Dako Immunostainer. Sections were
viewedonaNikonEclipseE600microscopeandimagescaptured
on a Nikon DXM1200 digital camera.
RESULTS
Inactivation of either p110α or p110β reduces PtdIns(3,4,5)P3 and
Akt activation upon PTEN loss in MEFs
We ﬁrst investigated whether the broadly expressed p110α or
p110β isoforms of PI3K regulate signalling induced by PTEN
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loss in MEFs, which mainly express p110α and p110β, with
little or no expression of p110γ and p110δ [29]. p110α was
inactivated genetically, using MEFs derived from intercrosses
of p110α
D933A/WT mice, which are heterozygous for a kinase-
inactivating germline knockin mutation in the ATP-binding site
of p110α (D933A; [28]) and PTEN
+/− mice. p110β in PTEN
+/−
MEFs was inactivated using the p110β-selective small molecule
inhibitor TGX-221 [30]. We tested both primary cells as well
as immortalized MEFs (stably expressing a shRNA-mir against
p53), the latter being more representative of a cancer cell status.
As expected, heterozygous PTEN inactivation in MEFs gave
rise to higher steady-state levels of PtdIns(3,4,5)P3, both in
primary and immortalized cells, under exponential growing
conditions (Figure 1A). This enhanced PtdIns(3,4,5)P3 level was
decreased to the same extent by inactivation of either p110α
or p110β (Figure 1A). In agreement with the higher levels of
PtdIns(3,4,5)P3, inactivation of PTEN led to enhanced phos-
phorylation of Akt on both Ser
473 and Thr
308 (Figure 1B).
Phosphorylation on both sites was reduced by inactivation of
p110α or p110β (Figure 1B).
Taken together, these data suggest that both p110α and
p110β can contribute to enhanced PtdIns(3,4,5)P3 synthesis
and downstream signalling upon inactivation of PTEN at the
cellular level.
Partial inactivation of p110α or p110β does not prolong survival of
PTEN+/− mice
PTEN
+/− mice develop tumours in many different tissues
[8–10]. We investigated whether inactivation of p110α or
p110β in PTEN
+/− mice would affect overall survival, by
crossing PTEN
+/− mice either with p110α
D933A/WT mice [28]
or p110β
D931A/WT mice (D931A is an inactivating mutation
in the ATP-binding site of p110β; J. Guillermet-Guibert
and B. Vanhaesebroeck, unpublished work). Homozygous
p110α
D933A/D933A mice or p110β
D931A/D931A mice are embryonic
lethal ([28] and J. Guillermet-Guibert and B. Vanhaesebroeck,
unpublished work). Heterozygosity for these p110 alleles results
in a partial inactivation of these PI3Ks [28,29], similar to what
could be realistically achieved by systemic administration of a
PI3K p110 isoform-selective pharmacological inhibitor.
Inactivation of p110α or p110β did not prolong overall
survival of heterozygous PTEN
+/− mice, compared with control
PTEN
+/− mice (Figure 2). The main reason for death was
killing the mice, necessitated by the development of lymphoma,
a predominant cancer in the PTEN
+/− model [8,31], which
occurred with a similar incidence and kinetics within the p110α
and p110β cohorts.
Partial inactivation of p110α or p110β reduces PtdIns(3,4,5)P3
levels without affecting lymphoma incidence
Despite the reduced levels of PtdIns(3,4,5)P3 in lymphoma
tissue isolated from PTEN
+/−×p110α
D933A/WT mice (Figure 3B),
inactivation of p110α did not affect lymphoma development
(Figure 3A), correlating with a minor or no impact on signalling
in tumour tissue derived from individual mice (Figure 3C).
Immunohistochemical analysis also showed no differences
in FOXO1 localization or intensity of reactivity for either
phosphorylation of Akt (pSer
473)o rS 6( p S e r
235/Ser
236)i n
lymphomas arising in PTEN
+/− and PTEN
+/−×p110α
D933A/WT
mice (results not shown).
Inactivation of p110β also did not affect lymphoma develop-
ment(Figure3D),butsubstantiallyreducedPtdIns(3,4,5)P3 levels
inPTEN
+/− lymphomatissue(Figure3E),withavariableimpact
Figure 1 PI3K signalling upon inactivation of p110α or p110β in MEFs
(A) Cellular PtdIns(3,4,5)P3 (PIP3) levels in primary (left-hand panel) and immortalized
(right-hand panel) MEFs of the indicated genotype. Where indicated, TGX-221 was added
at 500nM for 16h, with control PTEN+/− cells incubated with vehicle only. Results from
one experiment performed in triplicate are shown. The results shown are the means+ −S.E.M.
*P <0.05asobtainedbyStudent’st test(Mann–Whitney).(B)MEFsoftheindicatedgenotype
were cultured in 10% FBS in the presence of 500nM TGX-221 or vehicle for 16 h, followed by
cell lysis and immunoblotting with the indicated antibodies against Akt.
on Akt/mTOR (mammalian target of rapamycin) signalling,
which was often reduced (Figure 3F).
It is possible that the observed level of reduction in PI3K
pathway signalling by p110α or p11β inactivation is insufﬁcient
to impact on lymphoma development, or that these lymphomas
are/have become PI3K-independent and are unaffected by the
reduction in PtdIns(3,4,5)P3 levels induced by p110α or p110β
inactivation.
Inactivation of p110β, but not of p110α, delays the development of
PIN (prostatic intra-epithelial neoplasia) and prostate cancer
induced by PTEN loss
We next assessed the impact of inactivation of p110α or p110β
on prostate cancer and PIN, a premalignant proliferation arising
c   The Authors Journal compilation c   2012 Biochemical Society © 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.154 I. M. Berenjeno and others
Figure 2 Impact of inactivation of one allele of p110α or p110β on survival
of PTEN+/− mice
(A) Survival curves of PTEN+/− and PTEN+/−×p110αD933A/WT mice. The number of
mice used were: PTEN+/−, n=31 (16 females, 15 males); and PTEN+/−×p110αD933A/WT,
n=29 (12 females, 15 males) (Mantel–Cox test, P =0.2036; Gehan–Breslow–Wilcoxon test,
P =0.2617).(B)SurvivalcurveofPTEN+/− andPTEN+/−×p110βD931A/WTmice.Thenumber
of mice used were: PTEN+/−, n=16 (6 females, 10 males); and PTEN+/−×p110βD933A/WT,
n=14 (8 females, 6 males) (Mantel–Cox test, P =0.3380; Gehan–Breslow–Wilcoxon test,
P =0.1279). †the p110β cohort was terminated at 42weeks of age.
within the prostate. Inactivation of p110β, but not of p110α,h a s
previously been shown to protect from this pathology induced
by prostate-speciﬁc loss of PTEN [25]. In line with this previous
study, in which p110α or p110β were homozygously inactivated,
we observed a clear reduction in the frequency of PIN (from
10% to 0%) and prostate cancer (from 40% to 17%) upon
heterozygousinactivationofp110β,butnotofp110α(Figure4A).
We next investigated whether the isoform-speciﬁc impact of
PI3K inactivation on prostate cancer development correlated with
an isoform-speciﬁc effect on PtdIns(3,4,5)P3 levels in this tissue.
This was analysed in young (8–10-week-old) mice, before they
develop PIN or prostate cancer.
Compared with PTEN
+/− prostates, inactivation of p110α in a
PTEN
+/−context did not noticeably affect PtdIns(3,4,5)P3 levels
(Figure 4B). The impact of p110β inactivation on PtdIns(3,4,5)P3
levels was more variable. In fact, we frequently observed
increased PtdIns(3,4,5)P3 levels upon p110β inactivation
compared with WT mice, not only in the prostate (Figure 4B,
right-hand panel), but also in the other tissues where this
parameter was analysed, namely in uterus (Figure 4C) and
thyroid (Figure 4D). Increases in PtdIns(3,4,5)P3 were not
seen upon p110α inactivation, e.g. in prostate (Figure 4B)
and thyroid (Figure 5C). In the context of PTEN inactivation,
p110β co-inactivationledtoabroadvariabilityinPtdIns(3,4,5)P3
levels, which were substantially increased in some of the
mice (Figure 4B). It cannot be excluded that such enhanced
PtdIns(3,4,5)P3 production could contribute to protection from
cancer, for example by induction of senescence due to high Akt
activity [32,33].
p110α inactivation protects from the development of
glomerulonephritis, pheochromocytoma and thyroid cancer upon
PTEN inactivation
We next explored the impact of p110α inactivation on
tumours in PTEN
+/− mice other than prostate and lymphoma.
Histopathological analysis showed that PTEN
+/−×p110α
D933A/WT
mice developed a broad spectrum of tumours in different tissues,
similar to PTEN
+/− mice (Figure 5A).
Interestingly, the impact of p110α inactivation appeared to
differ among tumour types. Indeed, whereas the incidence of
several tumour types was unaffected (PIN, prostate cancer,
lymphoma, thymic hyperplasia and breast cancer), that of others
waseitherslightlyincreased(endometrialhyperplasia)orreduced
(pheochromocytoma and thyroid tumours) (Figure 5A). The
non-neoplastic immune-mediated glomerulonephritis was also
reduced by p110α inactivation (Figure 5A). No clear correlation
with time of tumour incidence was observed, although thymic
hyperplasia and phaeochromocytoma may occur at a later age
uponp110α inactivation(Figure5B).Takentogether,thechanges
in tumour incidence indicate that p110α can functionally interact
with PTEN tumourigenesis in vivo in a tissue-speciﬁc manner.
In the thyroid, a tissue in which inactivation of p110α
protects from PTEN loss-induced cancer (Figure 5A),
PtdIns(3,4,5)P3 levels in young (8–10 weeks of age) mice were
similar in PTEN
+/− and PTEN
+/−×p110α
D933A/WT mice, again
demonstrating the poor prognostic value of tissue PtdIns(3,4,5)P3
levels for subsequent cancer development.
DISCUSSION
Ever since the discovery of PTEN as one of the most commonly
inactivated genes in cancer, studies have been undertaken to
deﬁne the effectors involved in tumourigenesis driven by PTEN
inactivation. Mice with global or tissue-speciﬁc inactivation of
PTEN have been a key tool in these investigations. Signalling
proteinsidentiﬁedtoplayaroleinthetumour-suppressiveactivity
of PTEN include PDK1 (phosphoinositide-dependent kinase 1)
[31],Akt1[34],mTORC1(mTORcomplex1)andmTORC2[35–
40] and LKB1 (liver kinase B1)–AMPK (AMP-activated protein
kinase) [41].
Relatively less effort has been undertaken to assess the roles of
the different class I PI3K isoforms in the signalling and biology
induced by PTEN inactivation. This is surprising, given that these
PI3Ks generate the PtdIns(3,4,5)P3 lipid substrate for PTEN,
and that they are ultimately the most proximal mediators of
the lipid kinase-dependent impact of PTEN inactivation. Class I
PI3Ks include the p110α, p110β, p110γ and p110δ isoforms, of
which p110α and p110β are ubiquitously expressed, with p110δ
and p110γ being mainly found in leucocytes. p110δ and p110γ
have been functionally linked to PTEN in untransformed B-cells
(p110δ; [42]) and endothelial cells (p110γ; [43]), but their roles
incancerinducedbyPTENdeﬁciencyhavenotbeeninvestigated.
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Figure 3 PtdIns(3,4,5)P3 levels and PI3K/Akt signalling in PTEN+/−×p110αD933A/WT and PTEN+/−×p110βD931A/WT lymphomas
(A)IncidenceoflymphomainPTEN+/−×p110αD933A/WT (n=30)andlittermatecontrolPTEN+/− mice(n=27).(B)PtdIns(3,4,5)P3 levelsinlipidextractsisolatedfromPTEN+/−×p110αD933A/WT
andcontrolPTEN+/− lymphomatissuefromage-matchedmice.Numberoftissuesamplesused:PTEN+/−,n=9;andPTEN+/−×p110αD933A/WT,n=10.*P <0.05asobtainedbytheStudent’s
t test (Mann–Whitney). (C) Lymphoma protein extracts from the indicated mice were immunoblotted with the indicated antibodies. Tumour samples from four different mice were analysed
per genotype. The PtdIns(3,4,5)P3 (PIP3) levels in each sample are indicated. (D) Incidence of lymphoma in PTEN+/−×p110βD931A/WT mice (n=14) and littermate control PTEN+/− mice
(n=20). (E) PtdIns(3,4,5)P3 levels in lipid extracts isolated from PTEN+/−×p110βD933A/WT and control PTEN+/− lymphoma tissue from age-matched mice. Number of tissue samples used:
PTEN+/−×p110βD931A/WT,n=5;andPTEN+/−,n=10.*P <0.05asobtainedbytheStudent’st test(Mann–Whitney).(F)Lymphomaproteinextractsfromtheindicatedmicewereimmunoblotted
with the indicated antibodies. Tumour samples from four different mice were analysed per genotype. The PtdIns(3,4,5)P3 levels in each sample are indicated.
This also applies to p110α, whose role in this context has only
beeninvestigatedinamodelofselectivePTENlossintheprostate,
where it does not appear to be of functional importance in bloc-
king cancer development, in contrast with p110β [25]. PTEN-
deﬁcient cancer cell lines from different tissue origins (prostate,
breast and glioblastoma) have also been shown to mainly depend
on p110β and not p110α for their proliferation [23,24].
In order to investigate whether inhibition of p110α would
impact on the development of cancer driven by PTEN loss, we
crossed PTEN
+/− mice with mice heterozygous for the p110α
kinase-dead D933A knockin allele [28]. These p110α
D933A/WT
mice have a 50% reduction in p110α activity in all of
the tissues where it is expressed [28], mimicking the impact
of a systemically administered p110α-selective irreversible
ATP-competitive inhibitor. MEFs derived from PTEN
+/− and
PTEN
+/−×p110α
D933A/WT embryos were used as model cell lines
to document that p110α inactivation can inhibit the impact
of PTEN loss, namely by reducing the increased levels of
PtdIns(3,4,5)P3 and associated Akt signalling under steady-
state growth conditions (Figure 1). At the organismal level,
PTEN
+/−×p110α
D933A/WT mice developed a similar spectrum
of tumours as PTEN
+/− mice (Figure 5A) and had a similar
lifespan, mainly because both groups developed lymphoma with
asimilarincidenceasinPTEN
+/− controlmice(lymphomaisthe
most frequent cancer in the PTEN
+/− model [8,31], becoming
apparent within 15–20 weeks, often with large tumours that
necessitated the early killing of the mice). In other cancer types,
inactivation of p110α was found to have a differential impact.
For example, it did not affect the incidence of PIN and prostate
cancer,whichwefoundtobereducedbyubiquitousheterozygous
geneticinactivationofp110β,inagreementwithpreviousﬁndings
of homozygous inactivation of p110β [25]. The incidence of
glomerulonephritis, phaeochromocytoma and thyroid cancer in
PTEN
+/− mice, however, was reduced upon co-inactivation of
one p110α allele. Taken together, these results show that p110α
can functionally interact with PTEN in a signalling and cancer
context, and that even partial inactivation of p110α can confer
protection from cancer development in speciﬁc tissues.
The reason for a tissue-speciﬁc link of p110α and p110β
with cancer due to PTEN loss is unclear at the moment. This
observation might imply that treatment with p110 isoform-
speciﬁc PI3K inhibitors could be therapeutically beneﬁcial in
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Figure 4 Impact of inactivation of one allele of p110α or p110β on the development of PIN and prostate cancer, and on PtdIns(3,4,5)P3 levels in prostate,
uterus and thyroid tissue
(A) Incidence of PIN and prostate cancer in PTEN+/−×p110αD933A/WT mice (left-hand panel, closed bars) and PTEN+/−×p110βD931A/WT mice (right-hand panel, grey bars), compared with
PTEN+/− mice. Two independent PTEN+/− control cohorts were used, for the p110α (open bars) and the p110β mice (dotted bars). (B, C and D) PtdIns(3,4,5)P3 (PIP3) levels in prostate, uterus
and thyroid tissue from 8–10-week-old mice of the indicated genotypes. *P <0.05 as obtained by Student’s t test (Mann–Whitney).
the PTEN mutant cancer types in whose development these
PI3K isoforms have been implicated. However, it remains to
be documented whether the impact of PI3K inactivation on
established cancer is similar to that on cancer development.
Indeed, whereas germline organismal inactivation of PDK1
protects from cancer development in PTEN
+/− mice [31], no
sucheffectwasobservedwhenPDK1wasinactivatedpostnatally,
either concomitantly with or subsequent to PTEN inactivation
[44]. Moreover, although class I PI3K isoforms often have
non-overlapping functions in untransformed cells [3], this non-
redundancy is often lost in cancer cells [45,46]. For these reasons,
therapeutic interference with PI3K signalling in cancer may have
to target multiple PI3K isoforms, possibly simultaneously.
We hypothesized that a tissue-speciﬁc link of p110α and
p110β with cancer development in a PTEN
+/− context could
be due to a differential impact of p110α and p110β inactivation
on PtdIns(3,4,5)P3 lipid levels in different tissues. Given the
technical difﬁculties in measuring phosphoinositide lipids in
general, and in tissues in particular, this key parameter of
PI3K/PTEN signalling has, to the best of our knowledge, not
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Figure 5 Impact of p110α inactivation on PTEN+/− tumours and pathologies
(A) Tumour spectrum and incidence in PTEN+/− and PTEN+/−×p110αD933A/WT mice. Number of mice used: PTEN+/−, n=27 (14 females, 13 males); and PTEN+/−×p110α +/−, n=30
(14 females, 16 males). The tumours/pathologies are grouped according to either no change, slightly increased or decreased upon p110α inactivation. (B) Timing of appearance of some of the
tumours/pathologies shown in (A). (C) PtdIns(3,4,5)P3 (PIP3) levels in lipid extracts isolated from thyroid tissue from 8–10-week-old mice of the indicated genotypes.
been previously quantiﬁed in primary cancer tissues. Although
we appreciate that a more detailed PtdIns(3,4,5)P3 analysis is
to be considered, including the measurement of lipid levels at
differenttimepointsduringtumourdevelopment,theresultsofthe
present study indicate that there might not be a strict correlation
between tissue PtdIns(3,4,5)P3 levels and cancer development
or maintenance. Indeed, in many instances, PTEN
+/− tissues
did not have higher PtdIns(3,4,5)P3 levels than WT tissues.
Likewise, when PtdIns(3,4,5)P3 was monitored in established
PTEN
+/− lymphoma, partial inactivation of p110α and p110β
was found to decrease PtdIns(3,4,5)P3 levels (Figure 3B), yet
this had no discernable impact on tumour incidence (Figure 3A).
There was also a poor correlation between the impact of
PI3K isoform inactivation on tissue PtdIns(3,4,5)P3 levels before
cancer onset, and the cancer that eventually developed in these
tissues. For example, in PTEN
+/− thyroid tissues of 8–10-week-
old mice, inactivation of p110α did not affect PtdIns(3,4,5)P3
levels (Figure 5C); however, it reduced the incidence of this
tumour at an advanced age (>50 weeks; Figures 5A and 5B).
In the prostate, where inactivation of p110β provides some
protection (Figure 4A), the impact of p110β inactivation was
very variable, including increased PtdIns(3,4,5)P3 levels in some
cases (Figure 4B). It cannot be excluded that this enhanced
PtdIns(3,4,5)P3 production, although unexpected, may underpin
protection from cancer, for example by induction of senescence
due to high Akt activity [32,33].
Several possible explanations can be put forward for the
apparent lack of correlation between PtdIns(3,4,5)P3 levels and
tumour development and maintenance. In the case of lymphoma,
it is possible that the observed reduction in PtdIns(3,4,5)P3
levels may not be sufﬁcient to dampen signalling below the
necessary threshold for growth inhibition. It is also possible
that increases of PtdIns(3,4,5)P3 levels in the stroma, i.e. not
in the cancer cells themselves, may have facilitated lymphoma
development. It is also possible that some PTEN
+/− tumours do
not depend on loss of the lipid phosphatase activity of PTEN,
but on its protein phosphatase action [12–14] or its phosphatase-
independent activities in the nucleus [15,16]. It is also possible
that PtdIns(3,4,5)P3 measured in crude tissue extracts is not
the biologically relevant signalling pool at the subcellular level.
Indeed, evidence for the existence of different cellular pools
of PtdIns(3,4,5)P3 has been reported [47], possibly residing
in different subcellular compartments and with differential
sensitivity to the PTEN and SHIP2 [SH2 (Src homology 2)-
domain-containing inositol phosphatase 2] phosphatases, and
with differential capacities to activate Akt. It is therefore possible
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that inhibition of p110 isoforms in PTEN-null cells may alter
the subcellular localization of PtdIns(3,4,5)P3 pools, without
inducing changes in the overall PtdIns(3,4,5)P3 levels. Different
p110 isoforms might also control basal compared with growth
factor-stimulated Akt activity, as has been documented in PTEN-
deﬁcient prostate cancer cell lines in which p110α controls
heregulin-inducedAkt,whereasp110β,andtosomeextentp110δ,
control basal Akt activity [48]. Our observations from the present
study are reminiscent of the ﬁnding in colon cancer cell lines that
activating mutations in p110α do not signiﬁcantly alter growth
factor-stimulated or steady-state PtdIns(3,4,5)P3 levels under
normal cell culture conditions [49]. Likewise, many PIK3CA (the
gene encoding p110α) mutant cancer cell lines and human breast
tumours exhibit only minimal Akt activation [50]. In other words,
deregulation of p110α or PTEN in cancer does not necessarily
result in changes in overall cellular PtdIns(3,4,5)P3 levels or its
downstream signalling pathways.
In summary, our data show that p110α can, similarly to p110β,
functionally interact with PTEN in cultured cells, both in terms of
PI3K lipid production and signalling. In addition, inactivation
of p110α, in the context of a whole organism, can lead to
reduced development of some tumour types. However, no direct
correlation between steady-state levels of PtdIns(3,4,5)P3 and
cancer development was detected upon inactivation of p110α
or p110β. It is hoped that new technological developments to
monitor PtdIns(3,4,5)P3 levels in primary tissues [51] will be
instrumental in gaining further insight into the important question
of when and where alterations in PtdIns(3,4,5)P3 are of biological
relevance.
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